Her research focuses on democracy and the rule of law, homeland security, and diversity, equity, and inclusion. Katie Galgano is a former research assistant with the Executive Team at the Center for a New American Security (CNAS). Renewing the National Security Consensus.Enhancing DHS Oversight & Accountability.Constructing Regional Partnerships and Seizing Emerging Opportunities.Having an ingrained empathy and understanding of what it’s like moving around the world is something that, I believe, sets us apart. But also the incredible experiences, personal growth and opportunity it also offers.Īs we launch our new Global International Value proposition this week, focused on supporting International customers (whether that’s International students, investors or those moving around the world), we know how important our people are to helping our customers feel more at home. Those awkward moments, feeling alien, and alone. Having lived and worked in several countries myself, I know first hand how challenging, but also rewarding it can be. The culmination of many months of hard work from so many people across the bank – but with one common purpose: To celebrate our superpower, our Internationalism, our diversity and rich cultural heritage. It’s been quite emotional seeing all the incredible photos flooding in from around the world over the last 48hrs, following HSBC’s first ever global Internationalists Day. New drug combination offers ovarian cancer breakthrough “These initial results could be fantastic news for women with low-grade serous ovarian cancer, indicating a far more effective option than current treatments may be on the horizon.” It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.ĭr Susana Banerjee, consultant medical oncologist at the Royal Marsden and the global lead investigator of the study presented the findings at #ASCO23 today. Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. The international RAMP 201 study, led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, tested the drug avutometinib alone and in combination with defactinib. NEWS: Some women with ovarian cancer could benefit from a new targeted drug combination, which researchers say could be twice as effective as next best treatment.
0 kommentar(er)
